A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic non - squamous NSCLC with EGFR mutations and high PD-L1 expression.
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer|PD-L1 Positive
DRUG: Limertinib+bevacizumab|DRUG: Limertinib
PFS, the investigator assessed PFS, About 2 years
ORR, the investigator assessed objective response rate, about 6 month|OS, About 2 years
A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic non - squamous NSCLC with EGFR mutations and high PD-L1 expression.